Cwm LLC Raises Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Cwm LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 41.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,867 shares of the medical research company’s stock after purchasing an additional 550 shares during the quarter. Cwm LLC’s holdings in Natera were worth $117,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. abrdn plc purchased a new position in Natera during the 4th quarter valued at approximately $3,214,000. Oliver Lagore Vanvalin Investment Group lifted its stake in shares of Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Natera by 15.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,844 shares of the medical research company’s stock valued at $1,494,000 after purchasing an additional 3,228 shares during the last quarter. WCM Investment Management LLC lifted its stake in shares of Natera by 101.2% in the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after purchasing an additional 73,419 shares during the last quarter. Finally, Cerity Partners LLC lifted its stake in shares of Natera by 1,043.3% during the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after acquiring an additional 82,514 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $97.21 on Tuesday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The stock has a market cap of $11.74 billion, a price-to-earnings ratio of -25.65 and a beta of 1.38. The company has a 50 day simple moving average of $91.02 and a two-hundred day simple moving average of $70.07.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. As a group, analysts predict that Natera, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on NTRA shares. The Goldman Sachs Group raised their price target on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Canaccord Genuity Group raised their price target on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, May 1st. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a research note on Friday, April 5th. Finally, Stephens reaffirmed an “overweight” rating and set a $78.00 target price on shares of Natera in a research report on Tuesday, January 30th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

Insider Buying and Selling at Natera

In other Natera news, insider Daniel Rabinowitz sold 35,307 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the transaction, the insider now directly owns 204,218 shares of the company’s stock, valued at $15,334,729.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Herm Rosenman sold 93,901 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $69.37, for a total value of $6,513,912.37. Following the transaction, the director now directly owns 61,685 shares of the company’s stock, valued at $4,279,088.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Daniel Rabinowitz sold 35,307 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the completion of the transaction, the insider now directly owns 204,218 shares in the company, valued at $15,334,729.62. The disclosure for this sale can be found here. Insiders have sold a total of 380,750 shares of company stock valued at $31,864,820 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.